Back to Results

Infinity Pharmaceuticals Inc (INFIQ)

Infinity Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing cancer medicines. Its lead candidate, eganelisib (IPI-549), is an oral immuno-oncology therapy that targets PI3K-gamma and has been studied in Phase 2 trials for metastatic triple negative breast cancer and urothelial cancer, as well as in Phase 1/1b studies for solid tumors. The company has also worked through alliances with Intellikine, Verastem, and PellePharm, along with collaboration agreements with F. Hoffmann-La Roche and Bristol Myers Squibb. Founded in 1995 and headquartered in Cambridge, Massachusetts, Infinity Pharmaceuticals filed for Chapter 11 reorganization in September 2023, and the case was later approved as a Chapter 11 liquidation in March 2024.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Analyst Price Target Analyst Target Upside/Downside Overall Financial Health Dividend Yield Next Earnings Date Market Cap
OTC-INFI.Q
Not available
Not available
Not available
Weak
0.0%
November 16, 2026
0.09 K
Valuation • Fair Value

Infinity Pharmaceuticals Inc (OTC-INFI.Q) Fair Value by Valuation Model

No usable valuation estimate is currently available for Infinity Pharmaceuticals Inc (OTC-INFI.Q); fair value and analyst target coverage statuses are shown explicitly below.

Primary Valuation Read

Fair Value

Not available

Data is currently unavailable.

Analyst Price Target

Not available

Data is currently unavailable.

How to read these valuation models

No usable valuation estimate is currently available for Infinity Pharmaceuticals Inc (OTC-INFI.Q). Fair value and the analyst target remain visible as coverage-status fields and should not be read as valuation signals while unavailable.

Profitability • Growth

Profitability & Growth for Infinity Pharmaceuticals Inc (OTC-INFI.Q)

Review the profitability and growth indicators currently supported by the latest data.

Revenue Forecast

18 M

Forward revenue estimate.

EBITDA

0 K

Current operating profitability reference.

EBITDA Forecast

471.4 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Infinity Pharmaceuticals Inc (OTC-INFI.Q) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Infinity Pharmaceuticals Inc (OTC-INFI.Q)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Weak

Financial pressure deserves closer review.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Infinity Pharmaceuticals Inc (OTC-INFI.Q). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Infinity Pharmaceuticals Inc (OTC-INFI.Q)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

November 16, 2026

Days to Earnings

59

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for Infinity Pharmaceuticals Inc (OTC-INFI.Q), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Infinity Pharmaceuticals Inc (OTC-INFI.Q) Stock Forecast & Technical Outlook

Review Infinity Pharmaceuticals Inc (OTC-INFI.Q) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Infinity Pharmaceuticals Inc (OTC-INFI.Q) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Infinity Pharmaceuticals Inc (OTC-INFI.Q) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Infinity Pharmaceuticals Inc (OTC-INFI.Q) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Infinity Pharmaceuticals Inc (OTC-INFI.Q)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Hold

Based on the available recommendation mix, Infinity Pharmaceuticals Inc (OTC-INFI.Q) has a Hold consensus, with 0 buy, 1 hold and 0 sell recommendations in the current data set.

Buy 0
Hold 1
Sell 0
FAQ • Fast Investor Answers

Infinity Pharmaceuticals Inc (OTC-INFI.Q) Stock FAQ

Data-supported answers about Infinity Pharmaceuticals Inc (OTC-INFI.Q), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
Not available
No reliable estimate from the currently supported inputs
Financial Health
Weak
Current financial-health read

A reliable fair value estimate is not currently available for Infinity Pharmaceuticals Inc (OTC-INFI.Q). This generally means the latest dataset does not contain enough valid inputs for the valuation models supported by PriceToWorth. The site does not substitute zero or publish an unsupported estimate; availability may change when updated financial data or applicable model inputs become available.

The current financial health read for Infinity Pharmaceuticals Inc (OTC-INFI.Q) is Weak. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Infinity Pharmaceuticals Inc (OTC-INFI.Q) is November 16, 2026.

The latest available data indicates no current dividend yield for Infinity Pharmaceuticals Inc (OTC-INFI.Q).

The current market capitalization listed for Infinity Pharmaceuticals Inc is 0.09 K.

The ticker symbol for Infinity Pharmaceuticals Inc is OTC-INFI.Q, and the stock is listed on OTC Markets.

Infinity Pharmaceuticals Inc (OTC-INFI.Q) is listed on OTC Markets.

Similar Biotechnology Stocks View more on OTC Markets

Comparable companies from the same industry, limited to one security per issuer.

ABBV NYSE AbbVie Inc Fair Value Fair Market Cap 466.4 B
AMGN NASDAQ Amgen Inc Fair Value Fair Market Cap 208.5 B
GILD NASDAQ Gilead Sciences Inc Fair Value Fair Market Cap 186 B
VRTX NASDAQ Vertex Pharmaceuticals Inc Fair Value Fair Market Cap 128.8 B
REGN NASDAQ Regeneron Pharmaceuticals Inc Fair Value Undervalued Market Cap 78.353 B
ARGX NASDAQ argenx NV ADR Fair Value Fair Market Cap 62.595 B
MRNA NASDAQ Moderna Inc Fair Value Overvalued Market Cap 61.522 B
NTRA NASDAQ Natera Inc Fair Value Overvalued Market Cap 53.245 B
RVMD NASDAQ Revolution Medicines Inc Fair Value Fair Market Cap 40.928 B
ONC NASDAQ BeOne Medicines AG DRC Fair Value Fair Market Cap 39.9 B
ALNY NASDAQ Alnylam Pharmaceuticals Inc Fair Value Fair Market Cap 32.055 B
BIIB NASDAQ Biogen Inc Fair Value Fair Market Cap 31.841 B
ROIV NASDAQ Roivant Sciences Ltd Fair Value Overvalued Market Cap 28.748 B
INSM NASDAQ Insmed Inc Fair Value Fair Market Cap 26.206 B
INCY NASDAQ Incyte Corporation Fair Value Fair Market Cap 25.4 B
BNTX NASDAQ BioNTech SE Fair Value Fair Market Cap 24.131 B
UTHR NASDAQ United Therapeutics Corporation Fair Value Fair Market Cap 21.214 B
GMAB NASDAQ Genmab AS Fair Value Overvalued Market Cap 20.751 B
ASND NASDAQ Ascendis Pharma AS Fair Value Fair Market Cap 15.546 B
NBIX NASDAQ Neurocrine Biosciences Inc Fair Value Undervalued Market Cap 14.864 B